{
  "_id": "653d4dc6f37da825d671a347851108d8391ba8b655b41c2812c3107c4276e0f4",
  "feed": "wall-street-journal",
  "title": "Johnson & Johnson Suspends Covid Vaccine Sales Guidance, Citing Supply Surplus; In its consumer business, sales were hampered by supply constraints that mostly held back the company's skin-care and beauty-product lines",
  "text": "<p>The shot is one of three for Covid-19 authorized or approved in the U.S., but its use in the U.S. has lagged that of vaccines developed by other manufacturers. U.S. health regulators briefly paused the use of the vaccine in April of last year as they investigated rare blood-clotting conditions.</p><p>The company cut its full-year sales guidance from between $95.9 billion and $96.9 billion to between $94.8 billion and $95.8 billion. The company also slashed its adjusted earnings outlook from between $10.40 a share and $10.60 a share to between $10.15 a share and $10.35 a share.</p><p>Johnson &amp; Johnson Suspends Covid Vaccine Sales Guidance, Citing Supply Surplus</p>",
  "published": "2022-04-19T11:41:00.000Z",
  "tags": [
    {
      "id": "US4781601046",
      "nexusId": "10010560",
      "name": "Johnson & Johnson",
      "offsets": [
        {
          "start": 578,
          "end": 595
        },
        {
          "start": 0,
          "end": 17
        }
      ]
    }
  ]
}